Indivior Pharmaceuticals, Inc. INDV Cash Flow Statement
| FY'25 | FY'24 | FY'23 | ||
|---|---|---|---|---|
| $209M+2,886% | $7M+106% | -$126M-200% | ||
| $10M-37.5% | $16M+6.7% | $15M-6.3% | ||
| $26M+8.3% | $24M+14.3% | $21M+31.3% | ||
| -$46M-757% | $7M+111% | -$64M+38.5% | ||
| $19M— | —— | $0— | ||
| -$3M-400% | $1M-97.0% | $33M+57.1% | ||
| —— | $43M+617% | $6M-80.0% | ||
| -$49M— | —— | $418M+706% | ||
| —— | —— | $110M+210% | ||
| —— | —— | $0-100% | ||
| $10M— | —— | $0— | ||
| —— | —— | —— | ||
| -$27M— | —— | -$300M-7,400% | ||
| $66M+128% | $29M+263% | $8M+60.0% | ||
| $0— | $0-100% | $129M— | ||
| $19M-83.8% | $117M-9.3% | $129M+378% | ||
| $0— | $0+100% | -$3M-200% | ||
| $20M+17.6% | $17M-62.2% | $45M-81.6% | ||
| -$66M-196% | $69M+173% | -$95M+57.2% | ||
| —— | $173M+424% | $33M-63.3% | ||
| —— | $332M— | $0— | ||
| $17M-92.9% | $240M+1,900% | $12M+300% | ||
| —— | —— | $3M+50.0% | ||
| —— | —— | $22M+120% | ||
| —— | —— | $0— | ||
| —— | $2M— | $0— | ||
| -$30M— | —— | -$64M+36.6% | ||
| -$1M— | —— | $1M+200% | ||
| -$124M-4,233% | $3M+101% | -$459M-40.4% | ||
| $19M— | —— | $0— | ||
| -$1M-150% | $2M-80.0% | $10M+150% | ||
| —— | —— | $50M-74.6% | ||
| -$49M— | —— | $418M+706% | ||
| $10M— | —— | $0— | ||
| —— | —— | $0-100% | ||
| $0— | $0+100% | -$3M-200% | ||
| $20M+17.6% | $17M-62.2% | $45M-81.6% | ||
| $1M— | $0— | $0— | ||
| —— | $2M— | $0— | ||
| —— | —— | $0— | ||
| -$1M— | —— | $1M— | ||
| -$93M— | —— | -$308M-3,322% | ||
| -$93M— | —— | -$308M-3,322% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Indivior Pharmaceuticals, Inc. 's cash flow data come from?
- Every line is extracted from Indivior Pharmaceuticals, Inc. 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.